HUTCHMED (China) (HMDCF) Interest Coverage Ratio (2015 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Interest Coverage Ratio came in at 73.88 in Q2 2021, up 134.88% year-over-year from 31.45 in Q2 2020, and down 57.56% quarter-over-quarter from 174.05 in Q1 2021.
Powered by 
Analysis
HUTCHMED (China) (HMDCF) Interest Coverage Ratio (2015 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Interest Coverage Ratio for 4 consecutive years, with 73.88 the latest figure, recorded in Q2 2021.
- On a quarterly basis, Interest Coverage Ratio rose 134.88% year-over-year to 73.88 in Q2 2021; TTM through Jun 2021 was 457.34, a 95.69% increase from a year earlier, with the FY2025 full-year figure at 13.67, down 10.18% from the prior year.
- Interest Coverage Ratio was 73.88 for Q2 2021 at HUTCHMED (China), down from 174.05 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 184.42 in Q1 2020 and troughed at 211.78 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.84 Bn | 196.85 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 181.37 Bn | 178.19 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.46 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.71 Bn | 74.72 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 61.63 Bn | 56.45 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.66 Bn | 49.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.83 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.28 Bn | 29.99 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.30 Bn | 30.30 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 73.88 |
| Mar 31, 2021 | 174.05 |
| Jun 30, 2020 | -211.78 |
| Mar 31, 2020 | 184.42 |
| Jun 30, 2016 | -406.84 |
| Jun 30, 2015 | 293.01 |